GlassScriptPhysician profile
Michael Stanchina
NPI 1518989367
$219,230.74
in general payments reported to CMS, 2019-2025
22 companies · $35K in 2025
The $35K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,931 · 2020: $13K · 2021: $67K · 2022: $19K · 2023: $23K · 2024: $57K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Travel and Lodging: $7,020 · Consulting Fee: $6,156 · Food and Beverage: $3,483 · Education: $45.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,016.22 |
| Travel and Lodging | $7,019.85 |
| Consulting Fee | $6,156.00 |
| Food and Beverage | $3,483.41 |
| Education | $45.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $77,428.75 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $58,905.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $42,238.90 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Jazz Pharmaceuticals INC. | $20,256.05 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $19,012.02 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $573.62 | 2019-2025 | Nucala, Trelegy Ellipta |
| Resmed Corp | $157.06 | 2019 | |
| Insmed, INC. | $91.94 | 2019-2025 | Brinsupri, Arikayce |
| Axsome Therapeutics, INC. | $88.67 | 2024-2025 | Sunosi |
| Grifols USA, LLC | $75.81 | 2019-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $69.74 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $53.24 | 2019 | |
| Mylan Specialty L.P. | $42.00 | 2019 | |
| Inogen, INC. | $36.20 | 2025 | |
| Merck Sharp & Dohme LLC | $30.11 | 2025 | Zerbaxa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $29.60 | 2024 | Clonoseq |
| Baxter Healthcare | $29.16 | 2025 | Hillrom - Monarch Airway Clearance System |
| Abbvie INC. | $27.63 | 2023 | Avycaz |
| Vanda Pharmaceuticals INC. | $24.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.14 | 2019 | |
| Pfizer INC. | $19.17 | 2019 | |
| Amgen INC. | $17.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stanchina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.